EACS 2015: Dual Therapy with Protease Inhibitors and Lamivudine Suppresses HIV

Dual antiretroviral regimens consisting of only a boosted HIV protease inhibitor (lopinavir/ritonavir or atazanavir) and a single inexpensive and well-tolerated NRTI may be enough to achieve and maintain HIV suppression in a most patients starting antiretroviral therapy (ART) for the first time or switching from a standard triple regimen, according to a pair of studies presented at the EACS 15th European AIDS Conference last month in Barcelona.

alt

Read more:

EACS 2015: Does Low-level HIV Viral Load Raise the Risk of Disease Progression and Comorbidities?

HIV-positive people with detectable but low viral load -- in the range of 50 to 500 or 1000 copies/mL -- may continue to have a higher risk of AIDS-related events, but their likelihood of experiencing serious non-AIDS events including heart, liver, and kidney disease did not appear to increase, according to a pair of Italian studies presented at the 15th European AIDS Conference last month in Barcelona.

alt

Read more:

EACS 2015: Majority of Migrants with HIV in Europe May Have Acquired Virus in New Country

A study presented at the 15th European AIDS Conference last month in Barcelona found evidence that the majority of migrants living with HIV in Europe, and who were diagnosed less than 5 years ago, probably acquired the virus in their host country rather than the one in which they were born. The aMASE (Advancing Migrant Access to Health Services in Europe) study found that the proportion of people with a documented or probable date of HIV infection later than their move to, or within, Europe was higher than those with a documented or probable pre-migration infection date, and that this applied to all risk groups, all areas of origin, and both sexes.

alt

Read more:

EACS 2015: London Clinic Survey Shows Impact of Chemsex on Condom and PEP Use

A survey of gay men in London using drugs during sex -- known as "chemsex" --has shown high levels of unprotected sex and hepatitis C among both HIV-positive and HIV-negative men, high levels of post-exposure prophylaxis (PEP) use, and a high frequency of injection drug use, according to research presented at the 15th European AIDS Conference last month in Barcelona.

alt

Read more:

EACS 2015: Newest MDR-TB Drug Prices Could Fall by Up to 95% Through Generic Production

The cost of newer drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) could be cut by up to 95% if generic production of patented products could be achieved in the same way as for antiretroviral drugs, according to a study presented at the 15th European AIDS Conference last month in Barcelona. Price reductions might permit a 10-fold increase in the number of people who can be treated for MDR-TB within current budgets, without any new funding, the study suggests.

alt

Read more: